Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy

Rationale: The clinical use of PI3K inhibitors, such as buparlisib, has been plagued with toxicity at effective doses. The aim of this study is to determine if vitamin C, a potent epigenetic regulator, can improve the therapeutic outcome and reduce the dose of buparlisib in treating PIK3CA-mutated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mustafi, Sushmita, Camarena, Vladimir, Qureshi, Rehana, Sant, David W., Wilkes, Zachary, Bilbao, Daniel, Slingerland, Joyce, Kesmodel, Susan B., Wang, Gaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914363/
https://www.ncbi.nlm.nih.gov/pubmed/33664847
http://dx.doi.org/10.7150/thno.53225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914363/
https://www.ncbi.nlm.nih.gov/pubmed/33664847
http://dx.doi.org/10.7150/thno.53225

Ejemplares similares